Stoke Therapeutics Inc
NASDAQ:STOK
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3.79
17.52
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Stoke Therapeutics Inc
Wall Street
Price Targets
STOK Price Targets Summary
Stoke Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
STOK
is 22.73 USD
with a low forecast of 15.15 USD and a high forecast of 36.75 USD.
STOK Last Price Targets
Stoke Therapeutics Inc
The latest public price target was made on Oct 11, 2024 by
Marc Goodman
from
Leerink Partners
,
who expects
STOK
stock to
rise by 57%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
|
Marc Goodman
Leerink Partners
|
18
USD
Upside 57% |
1 month ago
Oct 11, 2024
|
Stoke Therapeutics assumed with an Outperform at Leerink
TheFly
|
|
Debjit Chattopadhyay
H.C. Wainwright
|
35
USD
Upside 206% |
2 months ago
Sep 11, 2024
|
H.C. Wainwright Reiterates Buy Rating on Stoke Therapeutics (STOK)
StreetInsider
|
Sumant Kulkami
Canaccord Genuity
|
20
USD
Upside 75% |
6 months ago
May 7, 2024
|
Stoke Therapeutics (STOK) PT Lowered to $20 at Canaccord Genuity
StreetInsider
|
Joseph Stringer
Needham
|
22
USD
Upside 92% |
7 months ago
Mar 26, 2024
|
Stoke Therapeutics (STOK) PT Raised to $22 at Needham, latest STK-001 'data put STOK in a strong position heading into regulatory discussions'
StreetInsider
|
|
Sumant Kulkami
Canaccord Genuity
|
21
USD
Upside 84% |
7 months ago
Mar 26, 2024
|
Stoke Therapeutics (STOK) PT Raised to $21 at Canaccord Genuity
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is STOK's stock price target?
Price Target
22.73
USD
According to Wall Street analysts, the average 1-year price target for
STOK
is 22.73 USD
with a low forecast of 15.15 USD and a high forecast of 36.75 USD.
What is Stoke Therapeutics Inc's Revenue forecast?
Projected CAGR
43%
The
compound annual growth rate
of Stoke Therapeutics Inc's revenue for the next 3 years is
43%.
You don't have any saved screeners yet
